Anthracycline-associated cardiotoxicity in survivors of childhood cancer

Pediatric Cardiology

Volumn 32, Issue 3, 2011, Pages 342-353

  Trachtenberg, Barry H ^a   Landy, David C ^a   Franco, Vivian I ^a   Henkel, Jacqueline M ^a   Pearson, Elliot J ^a   Miller, Tracie L ^a   Lipshultz, Steven E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Anthracyclines; Cardiotoxicity; Dexrazoxane

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMSACRINE; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BLEOMYCIN; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GROWTH HORMONE DERIVATIVE; IDARUBICIN; METOPROLOL SUCCINATE; MITOXANTRONE; PLACEBO; PREDNISOLONE; RAZOXANE; TRASTUZUMAB; TROPONIN; VALSARTAN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHILDHOOD CANCER; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DRUG EFFICACY; DRUG MONITORING; ENCAPSULATION; EVIDENCE BASED PRACTICE; GENETIC PREDISPOSITION; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RISK FACTOR; SARCOMERE; SURVIVOR;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; CARDIOTOXINS; DRUG TOXICITY; HUMANS; NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 79953732943     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00246-010-9878-3     Document Type: Conference Paper

References (98)

1. Adams MJ, Lipshultz SE (2005) Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 44:600-606 (Pubitemid 40629208)
2. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA (2009) Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 10:391-399
3. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention, and management. Expert Opin Pharmacother 8:1039-1058 (Pubitemid 46929299)
4. Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale BL, Clavell LA, Larsen EC, Moghrabi A, Sampson Y, Schorrin MA, Cohen HJ, Lipshultz SE, Sallan SE, Silverman LB (2008) Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 26:1106-1111
5. Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88:168-175 (Pubitemid 8282147)
6. Bruns LA, Chrisant MK, Lamour JM, Shaddy RE, Pahl E, Blume ED, Hallowell S, Addonizio LJ, Canter CE (2001) Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 138:505-511 (Pubitemid 32319723)
7. Bu'Lock FA, Mott MG, Oakhill A, Martin RP (1999) Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: a prospective study. Pediatr Cardiol 20:252-263 (Pubitemid 29279628)
8. Cardinale D, Sandri MT, Colombo A, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM (2004) Prognostic value of troponin-I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749-2754 (Pubitemid 38737923)
9. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-2481 (Pubitemid 44901520)
10. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55:213-220
11. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Hunt SAM, Fuster V, Jacobs AK, Gibbons RJ, Russell RO (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 16:1091-1110
12. Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB (2007) Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 7:114-121 (Pubitemid 47339857)
13. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Strarling RC, Towbin J, Virmani R (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 28:3076-3093 (Pubitemid 350262258)
14. Cowan JD, Neidhart J, McClure S, Coltman CA Jr, Grumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK (1991) Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 83:1077-1084
15. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, Ferreira-Martins J, Zheng H, Hosoda T, Rota M, Urbanek K, Kajstura J, Leri A, Rossi F, Anserva P (2010) Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121:276-292
16. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M (2008) Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol 130:688-695
17. Doroshow JH, Locker GY, Myers CE (1980) Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 65:128-135 (Pubitemid 10214339)
18. French Epirubicin Study Group (1988) A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6:679-688
19. Gabizon AA, Lyass O, Berry GJ, Wildgust M (2004) Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 22:663-669 (Pubitemid 40064725)
20. Geyer H, Caracciolo G, Abe H, Wilanksy S, Carerj S, Gentile F, Nesser HJ, Khandheria B, Narula J, Senguota PP (2010) Assessment of myocardial mechanics using speckle-tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr 23:351-369
21. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26:3777-3784
22. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE (1998) Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 27:53-68 (Pubitemid 28275509)
23. Gilladoga AC, Manuel C, Tan CT, Wollner N, Sternberg SS, Murphy ML (1976) The cardiotoxicity of adriamycin and daunomycin in children. Cancer 37(2 Suppl):1070-1078
24. Goorin AM, Chauvenet AR, Perez-Atayde AR, Cruz J, McKone R, Lipshultz SE (1990) Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 116:144-147 (Pubitemid 20038283)
25. Greenlee H, Hershman DL, Jacobson JS (2009) Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Res Treat 115:437-452
26. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, Yu Z, Ferrans VJ (1999) Correlation between serum levels of cardiac troponin-T and the severity of chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237-2243 (Pubitemid 29318858)
27. Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y, Gude NA, Thistlethwaite PA, Sussman MA, Gottlieb RA, Gustafsson AB (2010) Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation 121:675-683
28. Italian Multicentre Breast Study With Epirubicin (1988) Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol 6:976-982
29. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer Statistics, 2010. CA Cancer J Clin 5:277-300
30. Jurcut R, Wildiers H, Ganame J, D'hooge J, Paridaens R, Voigt JU (2008) Detection and monitoring of cardiotoxicity: what does modern cardiology offer? Support Care Cancer 16:437-445
31. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258-2262 (Pubitemid 44855419)
32. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S (2002) Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234-235:119-124 (Pubitemid 34777848)
33. Kanter MM, Hamlin RL, Unverferth DV, Davis HW, Merola AJ (1985) Effect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin. J Appl Physiol 59:1298-1303 (Pubitemid 16195344)
34. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 15:1544-1552 (Pubitemid 27167391)
35. Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM (2004) Antioxidants and cancer therapy: a systematic review. J Clin Oncol 22:517-528 (Pubitemid 41079781)
36. Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA (2005) Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol 207:436-444 (Pubitemid 43025692)
37. Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S (2009) Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast 18:218-224
38. Levitt G, Anazodo A, Burch M, Bunch K (2009) Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need? Eur J Cancer 45:3027-3034
39. Li J, Thompson TD, Miller JW, Pollack LA, Stewart SL (2008) Cancer incidence among children and adolescents in the United States, 2001-2003. Pediatrics 121:e1470-e1477
40. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter TM, Liao R, Sawyer DB (2004) Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279:8290-8299 (Pubitemid 38294721)
41. Lipshultz SE, Colan SD (2004) Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol 22:769-773 (Pubitemid 41103586)
42. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815
43. Lipshultz SE, Sanders SP, Colan SD, Goorin AM, Sallan SE, Krischer JP (1994) Monitoring for anthracycline cardiotoxicity. Pediatrics 93:433-437 (Pubitemid 24067017)
44. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Ssnders SP, Orav EJ, Gelber RD, Colan SD (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743
45. Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin B, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 20:1677-1682 (Pubitemid 34260550)
46. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145-153 (Pubitemid 38886649)
47. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD (2005) Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23:2629-2636 (Pubitemid 46179451)
48. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Sone SM, Gelber RD, Colan SD (2005) Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 20:4517-4522
49. Lipshultz SE, Vlach SA, Lipsitz SR, Sallan SE, Schwartz ML, Colan SD (2005) Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics 115:1613-1622 (Pubitemid 43843171)
50. Lipshultz SE, Walker VE, Torres SM, Walker DM, Barry E, Miller TL, Scully RE, Sallan SE (2007) Frequent mitochondrial DNA mutations and polymorphisms in long-term survivors of childhood acute lymphoblastic leukemia. Blood 118:824A
51. Lipshultz SE, Alvarez JA, Scully RE (2008) Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94:525-533 (Pubitemid 351441417)
52. Lipshultz SE, Rusconi P, Scully RE (2008) Chapter 18: assessment of cardiotoxicity during anticancer therapy. In: Januzzi JL, Bayes-Genis A (eds) NT-proBNP as a biomarker in cardiovascular diseases 2008. Prous Science. S.A.U., Barcelona, pp 1-15
53. Lipshultz SE, Scully RE, Smith HM, Anderson B, Safa R, Miller TL, Lipsitz SR, Sallan SE, Sawyer DB (2009) Serum cardiovascular growth factors during doxorubicin chemotherapy in children with leukemia (abstract). 5th world congress of paediatric cardiology and cardiac surgery (PCCS2009). Cairns, Australia, p 133
54. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale U, Clavell LA, Laverdiere C, Michon B, Schorin MA, Sallan SE (2010) Diagnostic value of cardiac troponin-T, N-terminal pro-brain natriuretic peptide, and high-sensitivity C-reactive protein during doxorubicin therapy in children with acute lymphoblastic leukemia (abstract). Circulation 122:A20432
55. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD (2010) Assessment of dexrazoxane as a long-term cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukemia: a prospective, randomized, multicenter trial. Lancet Oncol 11:950-961
56. Lowis S, Lewis I, Elsworth A, Weston C, Doz F, Vassal G, Bellott R, Robert J, Pein F, Ablett S, Pinkerton R, Frappaz D (2006) A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. Br J Cancer 95:571-580
57. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF (2007) Topoisomerase IIbeta-mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67:8839-8846
58. Mariotto AB, Rowland JH, Yabroff KR, Scoppa S, Hachey M, Ries L, Feuer EJ (2009) Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev 18:1033-1040
59. Meinardi MT, Van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van den Berg MP, Volkers C, Haaksma J, De Vries EG, Sleijfer DT, van der Graaf WT (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746-2753
60. Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME Jr, Ruccione K, Smithson WA, Robison LL (2001) Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 19:3163-3172
61. Miller TL, Lipsitz SR, Lopez-Mitnik G, Hinkle AS, Constine LS, Adams MJ, French C, Proukou C, Rovitelli A, Lipshultz SE (2010) Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 19:2013-2022
62. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229
63. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606
64. Nakamae H, Tsumura K, Terada Y, Nakane R, Nakamae M, Ohta K, Yamane T, Hino M (2005) Notable effects of angiotensin II receptor blocker, Valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104:2492-2498
65. Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD (2000) Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail 6:115-119
66. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572-1582
67. Olson RD, Li X, Palade P, Shadle SE, Mushlin PS, Gambliel HA, Fill M, Boucek RJ Jr, Cusack BJ (2000) Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol Appl Pharmacol 169:168-176
68. Petko C, Minich LL, Everitt MD, Holubkov R, Shaddy RE, Tani LY (2010) Echocardiographic evaluation of children with systemic ventricular dysfunction treated with carvedilol. Pediatr Cardiol 31:780-784
69. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815
70. Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, Skinner R, Stevens MC, Hawkins MM (2010) Longterm cause-specific mortality among survivors of childhood cancer. JAMA 304:172-179
71. Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, Redha E, Marin JR, Lon-Young M, Wolff GS (2004) Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant 23:832-838
72. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK (2008) New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100:1058-1067
73. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A (2000) Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11:1029-1033
74. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC (2010) Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 53:105-113
75. Shaddy RE, Olsen SL, Bristow MR, Taylor DO, Bullock EA, Tani LY, Renlund DG (1995) Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 129:197-199
76. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED, Dodd DA, Rosenthal DN, Burr J, LaSalle B, Holubkov R, Lukas MA, Tani LY (2007) Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 298:1171-1179
77. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin A, Rychik J, Hogarty AN, Cohen MI, Barber G, Rutkowski M, Kimball TR, DeLaat C, Steinherz LJ, Zhao H (2004) Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 22:820-828
78. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L, Cole PD, Kelly KM, Laverdiere C, Michon B, Schorin MA, Schwartz CL, O'Holleran EW, Neuberg DS, Cohen HJ, Sallan SE (2010) Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 24:320-334
79. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61:154-171
80. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, Barsotti A, Brunelli C (2004) Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37:837-846
81. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869-2879
82. Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S, Foley B, Bourge RC (2005) Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 24:2196-2201
83. Thompson KL, Rosenzweig BA, Zhang J, Knapton AD, Honchel R, Lipshultz SE, Retief J, Sistare FD, Herman EH (2010) Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother Pharmacol 66:303-314
84. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41:389-405
85. Trachtenberg BH, Hare JM (2009) Biomarkers of oxidative stress in heart failure. Heart Fail Clin 5:561-577
86. Tukenova M, Guibout C, Oberlin O, Doyon F, Mousannif A, Haddy N, Guerin S, Pacquement H, Aouba A, Hawkins M, Winter D, Bourhis J, Lefkopoulos D, Diallo I, de Vathaire F (2010) Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28:1308-1315
87. Unverferth DV, Jagadeesh JM, Unverferth BJ, Magorien RD, Leier CV, Balcerzak SP (1983) Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine. J Natl Cancer Inst 71:917-920
88. van WM, Neggers SJ, van der Lelij AJ, Pieters R, van den Heuvel-Eibrink MM (2010) The metabolic syndrome in adult survivors of childhood cancer, a review. J Pediatr Hematol Oncol 32:171-179
89. van Dalen EC, Caron HN, Dickinson HO, Kremer LC (2005) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 1:CD003917
90. van Dalen EC, Michiels EMC, Caron HN, Kremer LCM (2006) Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 4:CD005006
91. van Dalen EC, Michiels EM, Caron HN, Kremer LC (2010) Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 3:CD005006
92. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM (1977) Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Am J Med 62:200-208
93. Wallace KB (2007) Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 7:101-107
94. Walsh JM, Hussey J, Guinan E, O'Donnell D (2010) Pragmatic randomized controlled trial of individually prescribed exercise versus usual care in a heterogeneous cancer survivor population: a feasibility study PEACH trial: prescribed exercise after chemotherapy. BMC Cancer 10:42
95. Williams RV, Tani LY, Shaddy RE (2002) Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transplant 21:906-909
96. Wonders KY, Reigle BS (2009) Trastuzumab and doxorubicinrelated cardiotoxicity and the cardioprotective role of exercise. Integr Cancer Ther 8:17-21
97. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131:561-578
98. Zhou S, Palmeira CM, Wallace KB (2001) Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 121:151-157